Four leading MASLD patient advocates join Louise Campbell and Roger Green to discuss the role that MASLD patient advocates and others are likely to play in MASH drug access decisions, along with education and informational processes.
Four leading MASLD patient advocates join Louise Campbell and Roger Green to discuss the challenges in patient access and education that will follow the first MASH drug approval. expectations for the resmetirom PDUFA data and, with it, the potential for the first MASH drug approval.
Four leading MASLD patient advocates join Louise Campbell and Roger Green to discuss their expectations for the resmetirom PDUFA data and, with it, the potential for the first MASH drug approval.
Leading MASLD patient advocates Tony Villiotti of NASH kNOWledge, Wayne Eskridge of the Fatty Liver Foundation, Jeff McIntyre of the Global Liver Institute, and Milan Mishkevikj of the European Liver Patients Association join Louise Campbell and Roger Green to share their vision of changes in the MASH world in 2024 along with each organization’s hopes, concerns and plans. The discussion covers the advocates’ hopes and concerns for the year as well as the programs and efforts each considers top priority.
Surfing the MASH Tsunami continues its 2023 wrap-up conversations with Novo Nordisk International Medical Vice President Michelle Long, along with co-hosts Louise Campbell and Roger Green.
Surfing the MASH Tsunami continues its 2023 wrap-up conversations with biotech entrepreneur Rachel Zayas, Founder and CEO of AGED Diagnostics, along with co-hosts Louise Campbell and Roger Green.
Global Liver Institute Founder and CEO Donna Cryer joins Louise Campbell and Roger Green to discuss her personal challenges during the last part of 2023, the growing strength of the Global Liver Institute and the challenges facing GLI and the entire community in 2024.
Hepatology researcher, key opinion leader and 2023 UEG Rising Star of the Year Hannes Hagstrom joins Louise Campbell and Roger Green in a far-ranging discussion focusing largely on issues in diagnostics and clinical care pathways.
HistoIndex Chief Scientific Officer Dean Tai joins Jörn Schattenberg, Louise Campbell and Roger Green to discuss how advances in MASLD artificial intelligence will spur knowledge, insight and innovation in drug development and NITs.
Hepatology researcher and Key Opinion Leader Naim Alkhouri joins Louise Campbell and Roger Green to discuss advances in drug development and NITs and to share thoughts about efficacious use of clinical care pathways.
